Menu
Back to Journals » Biologics: Targets and Therapy » Volume 6
Ovarian cancer: emerging molecular-targeted therapies
Authors Sourbier C
Received 10 March 2012
Accepted for publication 13 April 2012
Published 20 June 2012 Volume 2012:6 Pages 147—154
DOI https://doi.org/10.2147/BTT.S24155
Review by Single anonymous peer review
Peer reviewer comments 2
Carole Sourbier
Rockville, MD, USA
Abstract: With about 22,000 new cases estimated in 2012 in the US and 15,500 related deaths, ovarian cancer is a heterogeneous and aggressive disease. Even though most of patients are sensitive to chemotherapy treatment following surgery, recurring disease is almost always lethal, and only about 30% of the women affected will be cured. Thanks to a better understanding of the molecular mechanisms underlying ovarian cancer malignancy, new therapeutic options with molecular-targeted agents have become available. This review discusses the rationale behind molecular-targeted therapies and examines how newly identified molecular targets may enhance personalized therapies for ovarian cancer patients.
Keywords: ovarian cancer, angiogenesis, PI3K/Akt, BRCA, metabolism
© 2012 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.